Clinical Trial Update: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of daratumumab, bortezomib, and dexamethasone in patients with plasmablastic lymphoma. The study is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmablastic Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Plasmablastic Lymphoma | Phase 2 | Status: RECRUITING